The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis
Open accessAbstract
BACKGROUND: Preventive therapy is a risk reduction option for women who have an increased risk of breast cancer. The effectiveness of preventive therapy to reduce breast cancer incidence depends on adequate levels of uptake and adherence to therapy. We aimed to systematically review articles reporting uptake and adherence to therapeutic agents to prevent breast cancer among women at increased risk, and identify the psychological, clinical and demographic factors affecting these outcomes. DESIGN: Searches were carried out in PubMed, CINAHL, EMBASE and PsychInfo, yielding 3851 unique articles. Title, abstract and full text screening left 53 articles, and a further 4 studies were identified from reference lists, giving a total of 57. This review was prospectively registered with PROSPERO (CRD42014014957). RESULTS: Twenty-four articles reporting 26 studies of uptake in 21 423 women were included in a meta-analysis. The pooled uptake estimate was 16.3% [95% confidence interval (CI) 13.6-19.0], with high heterogeneity (I(2) = 98.9%, P < 0.001). Uptake was unaffected by study location or agent, but was significantly higher in trials [25.2% (95% CI 18.3-32.2)] than in non-trial settings [8.7% (95% CI 6.8-10.9)] (P < 0.001). Factors associated with higher uptake included having an abnormal biopsy, a physician recommendation, higher objective risk, fewer side-effect or trial concerns, and older age. Adherence (day-to-day use or persistence) over the first year was adequate. However, only one study reported a persistence of ≥ 80% by 5 years. Factors associated with lower adherence included allocation to tamoxifen (versus placebo or raloxifene), depression, smoking and older age. Risk of breast cancer was discussed in all qualitative studies. CONCLUSION: Uptake of therapeutic agents for the prevention of breast cancer is low, and long-term persistence is often insufficient for women to experience the full preventive effect. Uptake is higher in trials, suggesting further work should focus on implementing preventive therapy within routine care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380 · cited 1×
“Study heterogeneity was assessed with Q statistics and I(2) estimations [24].”
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 1×
“Attempts to correct such beliefs have had mixed results [87 – 89], but several studies have indicated that necessity beliefs and concerns are amenable to change [90 – 92].”
Breast cancer statistics, 2013
DeSantis, C., Ma, J., Bryan, L., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21203 · Cited by 2,143
Ma, J., & Jemal, A. (2013) · Breast Cancer Metastasis and Drug Resistance · doi:10.1007/978-1-4614-5647-6_1 · Cited by 1,907
Pluye, P., & Hong, Q. N. (2014) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-032013-182440 · Cited by 1,363 · cited 1×
“The Mixed Methods Appraisal Tool (MMAT) can be used to assess study quality in mixed study reviews [20].”
Pace, R., Pluye, P., Bartlett, G., Macaulay, A. C., Salsberg, J., Jagosh, J., & Seller, R. (2012) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2011.07.002 · Cited by 1,331
Horne, R., Chapman, S. C. E., Parham, R., Freemantle, N., Forbes, A., & Cooper, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080633 · Cited by 1,174 · cited 1×
“These observations support a meta-analysis of the Necessity Concerns Framework, which showed lower adherence among patients who felt medication was an unnecessary part of their disease management, or among those who expressed greater concerns about the use of medication [86].”
Self-citationBreast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
Forouzanfar, M. H., Foreman, K. J., Delossantos, A. M., Lozano, R., Lopez, A. D., Murray, C. J. L., & Naghavi, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61351-2 · Cited by 1,009
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Powles, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05071-5 · Cited by 902
Veronesi, U. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04394-3 · Cited by 804
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0076 · Cited by 646
Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., & Howell, A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk049 · Cited by 534
Self-citationCuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A., Dowsett, M., Forbes, J. F., Ford, L., LaCroix, A. Z., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60140-3 · Cited by 495
Self-citationCuzick, J., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., Howell, A., & Forbes, J. F. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71171-4 · Cited by 464
Self-citationShared decision making about screening and chemoprevention
Sheridan, S. L., Harris, R. P., & Woolf, S. H. (2004) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2003.09.011 · Cited by 441
Day, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., & Fisher, B. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2659 · Cited by 438
Risk Factors for Breast Cancer for Women Aged 40 to 49 Years: A Systematic Review and Meta-analysis
Nelson, H. D., Zakher, B., Cantor, A., Fu, R., Griffin, J., O'Meara, E. S., Buist, D. S. M., Kerlikowske, K., van Ravesteyn, N. T., Trentham-Dietz, A., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-9-201205010-00006 · Cited by 425
Autier, P., Boniol, M., LaVecchia, C., Vatten, L., Gavin, A., Hery, C., & Heanue, M. (2010) · BMJ · doi:10.1136/bmj.c3620 · Cited by 412
Metcalfe, K. A., Birenbaum‐Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., Ghadirian, P., Foulkes, W. D., Klijn, J., Friedman, E., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23340 · Cited by 342
Petrie, K. J., Perry, K., Broadbent, E., & Weinman, J. (2012) · British Journal of Health Psychology · doi:10.1111/j.2044-8287.2011.02033.x · Cited by 330
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238648.23538.42 · Cited by 329
The past, present, and future of cancer incidence in the United States: 1975 through 2020
Weir, H. K., Thompson, T. D., Soman, A., Møller, B., & Leadbetter, S. (2015) · Cancer · doi:10.1002/cncr.29258 · Cited by 276
Puts, M. T. E., Tapscott, B., Fitch, M., Howell, D., Monette, J., Wan-Chow-Wah, D., Krzyzanowska, M., Leighl, N. B., Springall, E., & Alibhai, S. M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.010 · Cited by 264
Freedman, A. N., Graubard, B. I., Rao, S. R., McCaskill-Stevens, W., Ballard-Barbash, R., & Gail, M. H. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.7.526 · Cited by 260
Powles, T., Hardy, Jr., Ashley, S., Farrington, G., Cosgrove, D., Davey, J., Dowsett, M., McKinna, J., Nash, A., Sinnett, H., et al. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.235 · Cited by 246
Global Burden of Breast Cancer
Ferlay, J., Héry, C., Autier, P., & Sankaranarayanan, R. (2010) · Breast Cancer Epidemiology · doi:10.1007/978-1-4419-0685-4_1 · Cited by 240
Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, M. W., Vogel, V. G., Lee, M., Pajon, E. R., Wade, J. L., Dakhil, S., Lockhart, J. B., et al. (2006) · JAMA · doi:10.1001/jama.295.23.joc60075 · Cited by 238
Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis
Ropka, M. E., Keim, J., & Philbrick, J. T. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8077 · Cited by 230
Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review
Puts, M. T. E., Tu, H. A., Tourangeau, A., Howell, D., Fitch, M., Springall, E., & Alibhai, S. M. H. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt433 · Cited by 227
Wu, J. Y. F., Leung, W. Y. S., Chang, S., Lee, B., Zee, B., Tong, P. C. Y., & Chan, J. C. N. (2006) · BMJ · doi:10.1136/bmj.38905.447118.2f · Cited by 224
Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention
Port, E. R., Montgomery, L. L., Heerdt, A. S., & Borgen, P. I. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0580-9 · Cited by 196
Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
Chlebowski, R. T., Kim, J., & Haque, R. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0389 · Cited by 192
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
Waters, E. A., McNeel, T. S., Stevens, W. M., & Freedman, A. N. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2089-2 · Cited by 181
Fallowfield, L., Fleissig, A., Edwards, R., West, A., Powles, T. J., Howell, A., & Cuzick, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.1885 · Cited by 166
Self-citationBober, S. L., Hoke, L. A., Duda, R. B., Regan, M. M., & Tung, N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.192 · Cited by 156
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
Powles, T. J., Jones, A. L., Ashley, S. E., O'Brien, M. E. R., Tidy, V. A., Treleavan, J., Cosgrove, D. O., Nash, A. G., Sacks, N., Baum, M., et al. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689678 · Cited by 155
Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. Women
Waters, E. A., Cronin, K. A., Graubard, B. I., Han, P. K. J., & Freedman, A. N. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0930 · Cited by 144
Evans, D. G., Warwick, J., Astley, S., Stavrinos, P., Sahin, S., Ingham, S. L., McBurney, H., Eckersley, B., Harvie, M., Wilson, M., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0458 · Cited by 128
Self-citationImproving Adherence to Medication in Stroke Survivors: A Pilot Randomised Controlled Trial
O’Carroll, R. E., Chambers, J. A., Dennis, M. S., Sudlow, C. L. M., & Johnston, M. (2013) · Annals of Behavioral Medicine · doi:10.1007/s12160-013-9515-5 · Cited by 125
Karamanidou, C., Weinman, J. A., & Horne, R. (2008) · British Journal of Health Psychology · doi:10.1348/135910708x288792 · Cited by 116
Self-citationCheung, A. M., Tile, L., Cardew, S., Pruthi, S., Robbins, J. A., TOMLINSON, G. A., Kapral, M. K., Khosla, S., Majumdar, S., ERLANDSON, M. C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70389-8 · Cited by 107
Day, R. O., Ganz, P. A., & Costantino, J. P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1615 · Cited by 106
The Effect of Physician Recommendation on Enrollment in the Breast Cancer Chemoprevention Trial
Kinney, A. Y., Richards, C. L., Vernon, S. W., & Vogel, V. G. (1998) · Preventive Medicine · doi:10.1006/pmed.1998.0349 · Cited by 105
Zikmund‐Fisher, B. J. (2012) · Medical Care Research and Review · doi:10.1177/1077558712458541 · Cited by 105
Donnelly, L. S., Evans, D. G., Wiseman, J., Fox, J., Greenhalgh, R., Affen, J., Juraskova, I., Stavrinos, P., Dawe, S., Cuzick, J. M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.109 · Cited by 95
Self-citationPredicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention
Lin, J., Zhang, S. M., & Manson, J. E. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0380 · Cited by 88
Juraskova, I., Butow, P. N., Bonner, C., Bell, M. L., Smith, A. B., Seccombe, M., Boyle, F. M., Reaby, L., Cuzick, J. M., & Forbes, J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.144 · Cited by 86
Self-citationThe use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation
Metcalfe, K. A., Snyder, C., Seidel, J. H., Hanna, D., Lynch, H. T., & Narod, S. A. (2005) · Familial Cancer · doi:10.1007/s10689-005-4215-3 · Cited by 85
Acceptance of tamoxifen chemoprevention by physicians and women at risk
Tchou, J. C., Hou, N., RADEMAKER, A. W., Jordan, V. C., & Morrow, M. (2004) · Cancer · doi:10.1002/cncr.20205 · Cited by 85
Zwikker, H. E., van den Ende, C. H. M., van Lankveld, W. G., den Broeder, A. A., van den Hoogen, F. H. J., van de Mosselaar, B., van Dulmen, S., & van den Bemt, B. J. F. (2013) · Patient Education and Counseling · doi:10.1016/j.pec.2013.12.002 · Cited by 81
Fagerlin, A., Dillard, A. J., Smith, D., Zikmund‐Fisher, B. J., Pitsch, R. K., McClure, J. B., Greene, S. M., Alford, S. H., Nair, V. N., Hayes, D. F., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1450-1 · Cited by 78
Salant, T., Ganschow, P. S., Olopade, O. I., & Lauderdale, D. S. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00461.x · Cited by 75
Taylor, R., & Taguchi, K. (2005) · The Annals of Family Medicine · doi:10.1370/afm.284 · Cited by 73
Women's views on chemoprevention of breast cancer: qualitative study.
Heisey, R., Pimlott, N., Clemons, M. J., Cummings, S. R., & Drummond, N. (2006) · Europe PMC (PubMed Central) · Cited by 69
Mukattash, T. L., Hawwa, A. F., Trew, K., & McElnay, J. C. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0978-z · Cited by 68
Kinney, A. Y., Vernon, S. W., Frankowski, R. F., Weber, D. M., Bitsura, J. M., & Vogel, V. G. (1995) · Cancer · doi:10.1002/1097-0142(19950701)76:1<46::aid-cncr2820760107>3.0.co;2-b · Cited by 68
Phillips, K., Jenkins, M. A., Lindeman, G. J., McLachlan, S., McKinley, J. M., Weideman, P. C., Hopper, J. L., Friedlander, M., & kConFab Investigators (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00665.x · Cited by 67
Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, M. W., Vogel, V. G., Lee, M., Pajon, E. R., Wade, J. L., Dakhil, S. R., Lockhart, J. B., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238649.97517.22 · Cited by 66
Land, S. R., Cronin, W. M., Wickerham, D. L., Costantino, J. P., Christian, N. J., Klein, W. M. P., & Ganz, P. A. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0172 · Cited by 66
Pilot Trial of a Computerized Decision Aid for Breast Cancer Prevention
Ozanne, E. M., Annis, C. E., Adduci, K., Showstack, J. A., & Esserman, L. J. (2007) · The Breast Journal · doi:10.1111/j.1524-4741.2007.00395.x · Cited by 62
Matloff, E. T., Moyer, A. E., Shannon, K. M., Niendorf, K. B., & Col, N. F. (2006) · Journal of Women s Health · doi:10.1089/jwh.2006.15.843 · Cited by 60
Preventing breast and ovarian cancers in high‐risk BRCA1 and BRCA2 mutation carriers
Collins, I. M., Milne, R. L., Weideman, P. C., McLachlan, S., Friedlander, M. L., Hopper, J. L., & Phillips, K. (2013) · The Medical Journal of Australia · doi:10.5694/mja13.10848 · Cited by 58
Uptake of screening and prevention in women at very high risk of breast cancer
Evans, D. G., Lalloo, F. I., Shenton, A., Boggis, C. R. M., & Howell, A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06039-1 · Cited by 54
Signori, C., DuBrock, C., Richie, J. P., Prokopczyk, B., Demers, L. M., Hamilton, C., Hartman, T. J., Liao, J., El‐Bayoumy, K., & Manni, A. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2012.60 · Cited by 49
Korfage, I. J., Fuhrel-Forbis, A., Ubel, P. A., Zikmund‐Fisher, B. J., Greene, S. M., McClure, J. B., Smith, D. M., Alford, S. H., & Fagerlin, A. (2013) · Breast Cancer Research · doi:10.1186/bcr3468 · Cited by 48
Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
Cuzick, J. M., Šestak, I., & Thorat, M. A. (2015) · The Breast · doi:10.1016/j.breast.2015.07.013 · Cited by 42
Self-citationMetcalfe, K. A., Ghadirian, P., Rosen, B. P., Foulkes, W. D., Kim‐Sing, C., Eisen, A. F., Ainsworth, P., Horsman, D. E., Maugard, C. M., Provencher, D. M., et al. (2007) · PubMed Central · Cited by 39
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Vinayak, S., Schwartz, E., Jensen, K. C., Lipson, J. A., Alli, E., McPherson, L. A., Fernandez, A. M., Sharma, V. B., Staton, A. D., Mills, M. A., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2739-z · Cited by 36
Women's Decision Making About Whether or Not to Use Breast Cancer Chemoprevention
Altschuler, A., & Somkin, C. P. (2005) · Women & Health · doi:10.1300/j013v41n02_06 · Cited by 32
Pujol, P., Lasset, C., Berthet, P., Dugast, C., Delaloge, S., Fricker, J., Tennevet, I., Chabbert‐Buffet, N., This, P., Baudry, K., et al. (2011) · Familial Cancer · doi:10.1007/s10689-011-9484-4 · Cited by 32
Choice of Management of Southern Chinese BRCA Mutation Carriers
Kwong, A., Wong, C., Shea, C., Suen, D. T. K., & Choi, C. L. Y. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0477-5 · Cited by 26
Razzaboni, E., Toss, A., Cortesi, L., Marchi, I., Sebastiani, F., Matteis, E. D., & Federico, M. (2012) · The Breast Journal · doi:10.1111/tbj.12045 · Cited by 25
Loehberg, C. R., Jud, S. M., Haeberle, L., Heusinger, K., Dilbat, G., Hein, A., Rauh, C., Dall, P., Rix, N., Heinrich, S., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0845-8 · Cited by 25
Klepin, H. D., Geiger, A. M., Bandos, H., Costantino, J. P., Rapp, S. R., Sink, K. M., Lawrence, J. A., Atkinson, H. H., & Espeland, M. A. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0165 · Cited by 25
Becker, N. (2010) · Springer eBooks · doi:10.1007/978-3-540-69743-5_7 · Cited by 24
Uptake of breast cancer prevention and screening trials: Table 1
Evans, D. G., Harvie, M., Bundred, N. J., & Howell, A. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2010.082768 · Cited by 21
Veronesi, A., Pizzichetta, M. A., Ferlante, M. A., Zottar, M., Magri, M. D., Crivellari, D., & Foladore, S. (1998) · Tumori Journal · doi:10.1177/030089169808400312 · Cited by 20
Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention
Reimers, L., & Crew, K. D. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0082-8 · Cited by 18
Australian clinicians and chemoprevention for women at high familial risk for breast cancer
Keogh, L. A., Hopper, J. L., Rosenthal, D., et al. (2009) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-7-9 · Cited by 17
Risk scores and decision making: the anatomy of a decision to reduce breast cancer risk
Holmberg, C., Daly, M. B., & McCaskill‐Stevens, W. (2010) · Journal of Nursing and Healthcare of Chronic Illness · doi:10.1111/j.1752-9824.2010.01068.x · Cited by 12
Palva, T., Ranta, H., Koivisto, A., Pylkkänen, L. H., Cuzick, J. M., & Holli, K. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.015 · Cited by 11
Self-citationMetcalfe, K. A., Ghadirian, P., Rosen, B. P., Foulkes, W. D., Kim‐Sing, C., Eisen, A. F., Ainsworth, P., Horsman, D. E., Maugard, C. M., Provencher, D. M., et al. (2007) · Open medicine · Cited by 8
Cited by
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Self-citationDepression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 375
Machado, M. O., Veronese, N., Sanches, M., Stubbs, B., Koyanagi, A., Thompson, T., Tzoulaki, I., Solmi, M., Vancampfort, D., Schuch, F. B., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1101-z · Cited by 264
Nelson, H. D., Fu, R., Zakher, B., Pappas, M., & McDonagh, M. (2019) · JAMA · doi:10.1001/jama.2019.5780 · Cited by 137
Smith, S. G., Sestak, I., Howell, A., Forbes, J., & Cuzick, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7439 · Cited by 51
Self-citation
Metadata
- Authors
- Smith, S. G., Sestak, I., Forster, A., Partridge, A., Side, L., Wolf, M. S., Horne, R., Wardle, J., & Cuzick, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 27
- Issue
- 4
- Pages
- 575-590
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2195518879
- Cited by
- 263
- References
- 90
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.